Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen

Clinical Laboratory

Volumn 58, Issue 11-12, 2012, Pages 1211-1218

  Rolla, Roberta ^a,b   Vidali, M ^a,b   Meola, S ^b   Pollarolo, P ^b   Fanello, M R ^b   Nicolotti, C ^b   Saggia, C ^b   Forti, L ^b   Agostino, F D ^b   Rossi, V ^b   Borra, G ^b   Stratica, F ^b   Alabiso, O ^a,b   Bellomo, G ^a,b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Breast cancer; CYP450 2D6; DNA microarray; Side effects; Tamoxifen; Ultrarapid metabolizer phenotype

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DNA MICROARRAY; DNA POLYMORPHISM; DRUG METABOLISM; EARLY CANCER; ENDOMETRIAL THICKNESS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE DUPLICATION; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MUSCLE CRAMP; SIDE EFFECT; VAGINA DISEASE; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; EARLY DIAGNOSIS; FEMALE; GENOTYPE; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TAMOXIFEN;

EID: 84871571190     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.120114     Document Type: Article

References (41)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v1.2009.
3. Howell A, Cuzick J, Baum M, et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
4. Thürlimann B, Keshaviah A, Coates AS, et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57. (Pubitemid 43016814)
5. Xu HB, Liu YJ, Li L. Aromatase Inhibitor Versus Tamoxifen in Postmenopausal Woman With Advanced Breast Cancer: A Literature-Based Meta-Analysis. Clin Breast Cancer 2011;11:246-51.
6. Forrest AR. Aromatase inhibitors in breast cancer. N Engl J Med 2003;349:1090.
7. Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. Breast 2011;20:111-8. Review.
8. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009;9:576-86.
9. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85:151-9.
10. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64. (Pubitemid 38008898)
11. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has antiestrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005;55:471-8. (Pubitemid 40568978)
12. Buck MB, Coller JK, Murdter TE, Eichelbaum M, Knabbe C. TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Res Treat 2008;107:15-24. (Pubitemid 350179587)
13. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 2009;69:1722-7.
14. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-75. (Pubitemid 39108928)
15. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. Clin Oncol 2010;28:1287-93.
16. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-36.
17. Abraham JE, Maranian MJ, Driver KE, et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64.
18. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8.
19. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21. (Pubitemid 47555336)
20. Thompson AM, Johnson A, Quinlan P, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 2011;125:279-87.
21. Pérez DG, Zahasky KM, Loprinzi CL, et al. Tamoxifen-associated hot flashes in women. Support Cancer Ther 2007;4:152-6. (Pubitemid 47113854)
22. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001;97:855-66. (Pubitemid 32406196)
23. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37. (Pubitemid 38161221)
24. Serrano D, Lazzeroni M, Zambon CF, et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J 2011;11:100-7.
25. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.
26. Steams V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64. (Pubitemid 38008898)
27. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74. (Pubitemid 43946844)
28. Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006;24:3708-9. (Pubitemid 46630548)
29. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31. (Pubitemid 40051906)
30. Madadi P, Ciszkowski C, Gaedigk A, et al. Genetic transmission of cytochrome P450 2D6 (CYP2D6) ultrarapid metabolism: implications for breastfeeding women taking codeine. Curr Drug Saf 2011;6:36-9.
31. Bertilsson L, Dahl ML, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993;341:63. (Pubitemid 23007648)
32. Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63:444-52. (Pubitemid 28214968)
33. Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90. (Pubitemid 36798424)
34. Wu K, Brown P. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer? J Natl Cancer Inst 2003;95:766-7. Review. (Pubitemid 36798414)
35. de Lima GR, Facina G, Shida JY, et al. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 2003;39:891-8. (Pubitemid 36428620)
36. The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9.
37. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317-27. (Pubitemid 34831529)
38. Colleoni M, Gelber S, Goldhirsch A, et al. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006;24:1332-41. (Pubitemid 46621995)
39. Ortmann O, Cufer T, Dixon JM, et al. Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast 2009;18:2-7.
40. Montemurro F, Aglietta M, Del Mastro L. Aromatase inhibitors as adjuvant therapy for breast cancer. J Clin Oncol 2009;27:2566-7.
41. Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Cane Netw 2009;7:203-13.